News und Analysen

The obesity drug market is creating trillion-dollar winners, but you don't have to pay premium prices for exposure. Pfizer (NYSE: PFE) and Viking Therapeutics (NASDAQ: VKTX) are both relatively

Despite some volatility earlier in the year, 2025 has shaped up to be another impressive year for artificial intelligence (AI) stocks. Per usual, data analytics platform Palantir Technologies

Oncology is the largest therapeutic area in the pharmaceutical industry by sales, but right now, weight management is the hottest. This market is predicted to grow rapidly in the next decade

California-based TCG Crossover Management fully exited its position in Cidara Therapeutics (NASDAQ:CDTX) during the third quarter, reducing its holdings by 1 million shares in a move valued at

The healthcare sector is a highly competitive, highly regulated, and technically complex industry. Which is why most investors should probably stick to the industry's largest companies.

With a

Earnings season creates short-term winners and losers, companies whose shares rise or fall after they announce their quarterly updates. The good news is that among these short-term losers, there are

Vertex Pharmaceuticals (NASDAQ: VRTX) has not performed well for most of the year, and the company's latest quarterly update did nothing to turn things around. However, the market may be overlooking

Though it started the year strong, CRISPR Therapeutics (NASDAQ: CRSP) is experiencing a pullback. Over the past month, shares of the gene-editing specialist are down 23%. But there is plenty of

The last five or six years have been a roller-coaster ride for Pfizer (NYSE: PFE) and its shareholders. It was a fun ride on the way up, but after peaking in late 2021, the pharmaceutical giant's

On Nov. 14, 2025, 4D Advisors, LLC disclosed in a regulatory filing that it sold out its entire position in Masimo (NASDAQ:MASI). The sale was valued at $7.57 million.

According to a filing with the

The biotech industry is notoriously volatile. Drugmakers often face significant challenges that send their stocks plummeting. Sometimes that creates an attractive entry point, provided we can

Pfizer (NYSE: PFE) has been southbound for the past three years. Following its success in the coronavirus market, which made it the first company in the biopharma industry to generate $100 billion

The stock of pharmaceutical company Amgen (NASDAQ: AMGN) didn't exactly have a banner trading session on Thursday. In closing the day nearly flat, however, to notch a slight beat on the S&P 500

Biotech stocks have performed well this year. The SPDR S&P Biotech ETF -- an industry benchmark -- is up 21% this year. Two giants of the industry that have helped drive that performance are Amgen

Merck (NYSE: MRK) has a $210 billion market cap. Pfizer (NYSE: PFE) has a market cap of $135 billion. They are both pharmaceutical industry giants with long and successful histories behind them. But

As an old investing adage goes: Investors have lost more reaching for yield than at the point of a gun. That may sound a bit dramatic, but when you think of all the yield trap stocks -- high-yield

ResMed (NYSE: RMD) finds itself in an investment limbo as revolutionary weight loss drugs create both immediate opportunities and long-term existential questions for the sleep apnea device maker.

Meta Platforms (NASDAQ: META) has come a long way from its origins as a platform to connect students to its current status as a social media powerhouse and leader in the ongoing artificial

It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you

Innovative biopharmaceutical company Metsera (NASDAQ: MTSR) has been climbing all year. It went public on Feb. 3 of this year, priced at $18 per share, and immediately climbed above $27. It had been

On Tuesday, Amgen (NASDAQ: AMGN) stock hit its one-year high, on continued momentum from a far better-than-expected quarterly earnings report. The immediate catalyst was a post-earnings price target

Since last year, DexCom (NASDAQ: DXCM) has faced a series of issues that have sunk its stock price. The medical device specialist's shares are down 20% over the trailing-12-month period and are

The next three years have just become a bigger question mark for Pfizer (NYSE: PFE) than they were before. There are two competing factors taking shape, one internal to the drugmaker; the other is

As we wind down 2025, the markets are looking shaky and I want my portfolio to be well diversified in the case of a recession or market correction. As such, in today's video I am going to take all

A strong quarter and earnings beat can sometimes give a stock a big boost. But when that doesn't happen, it usually means there are other factors that are weighing on a business and give investors